ClinicalTrials.Veeva

Menu
S

SimcoDerm Medical and Surgical Dermatology Center | Barrie, Canada

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

CTP-543
Ruxolitinib
Ritlecitinib
ESK-001
PF-04965842
Povorcitinib
Upadacitinib
PF-06700841
Ustekinumab
XEN801

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 34 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Active, not recruiting
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. A...

Active, not recruiting
Alopecia Areata
Drug: Placebo - 50 mg
Drug: Ritlecitinib 50 mg

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.

Active, not recruiting
Prurigo Nodularis
Other: Matching Placebo
Biological: barzolvolimab

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Active, not recruiting
Prurigo Nodularis
Drug: Povorcitinib
Drug: Placebo

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.

Active, not recruiting
Prurigo Nodularis
Drug: Placebo
Drug: Povorcitinib

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Placebo
Drug: Upadacitinib

The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with at...

Active, not recruiting
Atopic Hand and Foot Dermatitis
Drug: Lebrikizumab
Drug: Placebo

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting
Alopecia Areata
Drug: CTP-543

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Active, not recruiting
Psoriasis
Severe Psoriasis
Drug: Open-Label Envudeucitinib
Drug: Blinded Envudeucitinib

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

Enrolling
Plaque Psoriasis
Drug: Ustekinumab
Drug: Deucravacitinib

Trial sponsors

Pfizer logo
Incyte logo
AbbVie logo
A
Amgen logo
Concert Pharmaceuticals logo
D
Akros Pharma logo
A
Bristol-Myers Squibb (BMS) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems